<DOC>
	<DOCNO>NCT00511368</DOCNO>
	<brief_summary>The purpose study evaluate antiretroviral activity five different oral dos administer two week bevirimat versus placebo HIV treatment experience patient , document genotypic resistance least one major mutation IAS-USA list ( 2007 ) resistance mutation NRTIs , NNRTIs , PIs . Patients also monitor side effect , pharmacokinetics bevirimat determine .</brief_summary>
	<brief_title>Phase 2 Safety Efficacy Study Bevirimat Functional Monotherapy HIV Treatment-Experienced Patients 2 Weeks*</brief_title>
	<detailed_description>Bevirimat ( PA103001-04 ) represent new class antiviral block HIV replication disrupt virus maturation ; specifically , inhibit late step Gag processing cascade . Short term ( 7-10 day ) functional monotherapy study ( conduct patient detectable viral load fail regimen ) help determine potency drug , enable dose find . This two part ( A B ) randomize , placebo-controlled , double-blind , multiple-dose , dose-escalation study HIV treatment-experienced patient fail regimen ( harbor resistance mutation least one member NRTI , NNRTI PI class . The antiretroviral activity , safety , pharmacokinetics 5 different dose level bevirimat compare placebo add fail approved antiretroviral regimen . The study conduct two part : A B . In Part A follow 14 day daily dose patient commence new optimized ART regimen addition randomize treatment . In Part Part B dose randomize treatment end initial 14 day daily dose .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Male female . Females childbearing potential , must document negative pregnancy test willing utilize doublebarrier contraception throughout study period . Have HIV1infection . Have screen plasma HIV1 RNA value , measure Roche Amplicor assay , 2,000 250,000 copies/ml ( inclusive ) . Have document evidence genotypic resistance medical record ( screen ) resistance screen genotype major mutation IASUSA list resistance drug mutation , define : NRTI resistance : M41L , K65R , D67N , K70R , K70E , L74V , Y115F , M184V , M184V/I , L210W , T215Y/F , K219Q/E ; NNRTI resistance : L100I , K103N , V106M , V106A/M , V108I , Y181C , Y181C/I , Y188L , Y188C/L/H , G190S/A , G190A , P225H ; Major PI resistance : D30N , V32I , L33F , M46I/L , I47V/A , G48V , I50L , I50V , I54M/L , L76V , V82A/F/T , V82A/F/T/S , V82L/T , I84V , N88S , L90M Be receive antiretroviral therapy regimen contain least 3 drug ( regimen contain ritonavir must exceed total daily dose 400 mg ) unchanged least 8 week prior initial screening . Be able receive optimize background regimen . Be free acute infection serious medical illness within 14 day prior study entry . Be informed nature study provide write informed consent . Be willing comply meal requirement describe protocol . Current opportunistic infection characteristic AIDS Patients unable unwilling comply dose schedule protocol evaluation . Patients malabsorption syndromes affect drug absorption . Patients systolic blood pressure &lt; 90 mmHg &gt; 140 mmHg diastolic blood pressure &lt; 60 mmHg &gt; 90 mmHg measure semirecumbent position least 10 minute rest screen qualification visit . A history seizure ( exclude pediatric febrile seizure ) , migraine , cluster and/or chronic headache , cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) . Patients abnormal Hemoglobin ( &lt; 10.0 g/dL men &lt; 9.0 g/dL woman ) , Neutrophil count ( &lt; 1000/mm3 ) , Platelet count ( &lt; 100,000/mm3 ) , AST ALT &gt; 2.5 time upper limit normal ( patient positive HBV surface antigen HCV antibody test screening must AST ALT 1.5 time upper limit normal ) Patients receive radiation therapy cytotoxic chemotherapeutic agent , immunomodulating agent , HIV immunotherapeutic vaccine , investigational drug product , participation drug study within 4 week prior first dose study drug . A history alcoholism drug addiction within past 1 year ( unless enrol treatment program approve sponsor ) . Recent use recreational drug ( except marijuana ) . A history difficulty donate blood inadequate venous access . The donation blood plasma within 30 day prior receive study medication . Note : patient CD4 count &lt; 100 cells/mm3 consider enrollment follow discussion agreement Investigator Sponsor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>HIV</keyword>
	<keyword>treatment experience</keyword>
	<keyword>AIDS</keyword>
</DOC>